Le Lézard
Classified in: Health
Subjects: PLW, MRR

4 Day Drafting Effective Pharmaceutical Patents Training Course: Explore the Latest Strategies and Gain Useful Insights and Practical Solutions to Your Drafting Issues (May 16-19, 2023)


DUBLIN, April 7, 2023 /PRNewswire/ -- The "Drafting Effective Pharmaceutical Patents Training Course" conference has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The highly complex area of pharmaceutical patents is looked at in detail in this course. The expert faculty will take you through the key differences between the European and US systems and how these can impact your patents.

They will explore the latest strategies and give you useful insights and practical solutions to your drafting issues. By understanding the importance of aligning your patent and regulatory strategies, you will improve your pharmaceutical claim drafting skills to the best advantage.

The practical claim drafting exercises included in the course will give you an opportunity to get to grips with the information in a safe environment and under the guidance of the trainers. They will help embed what you have learnt so that it can be taken back to the workplace and put into practice.

As well as receiving inside knowledge and top tips and advice from the highly experienced professionals from industry and private practice, the course also provides a valuable opportunity to network with others in similar roles from different companies. By attending, you can discuss your challenges with colleagues and our expert faculty and find solutions to your questions.

Key topics covered in this intensive training programme include:

Who Should Attend:

Key Topics Covered:

Summary of the course

Drafting primary patents - small molecules

Drafting primary patents - biologics

Primary patents workshop

Drafting with a focus towards interplay with regulatory issues

Data needed to support patent applications

Secondary patents

Secondary patents workshop

Speaker

Anthony Tridico
Managing Partner
Finnegan's European office in London

Dr. Anthony Tridico is the Managing Partner of Finnegan's European office in London and has over 20 years of experience protecting pharmaceutical inventions. Anthony practices all aspects of intellectual property law, from strategic patent portfolio management to litigation including strategic client counselling, due diligence investigations, patent portfolio management and analysis, prosecution and drafting, and appeals and oral hearings at the Patent Trial and Appeal Board (PTAB).

He also offers expertise in representing clients in the specialised areas of FDA Orange Book listing of patents, and patent term extensions. Anthony has served for over 15 years as adjunct professor at Georgetown University Law School teaching patent law and patent prosecution and he has been recognized by Intellectual Asset Management as a leading patent prosecutor in the United Kingdom and Europe in the IAM Patent 1000, and as a top IP strategist by the IAM Strategy 300. Managing Intellectual Property named him an "IP Star" in the United Kingdom.

For more information about this conference visit https://www.researchandmarkets.com/r/2v2u2g

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:00
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...

at 08:05
GE HealthCare today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR...

at 07:00
To mark National Hospice Palliative Care Week, the Quebec Coalition for Palliative Care Access (the Coalition) is proud to celebrate the positive impact of palliative care on the well-being of people with life-limiting illness. Palliative care is...

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...



News published on and distributed by: